The mutant IDH1/2 found in human cancer not only have lost their normal catalytic activity but also conferred a neomorphic enzymatic gain-of-function: the NADPH-dependent reduction of α-KG to D-2-hydroxyglutarate (D-2-HG), a trace metabolite in normal cells [7, 8]. The gene discussed is IDH1; the disease is cancer.